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Abstract
The (CGG)n-repeat in the 50-untranslated region of the fragile X mental retardation gene (FMR1) gene is polymorphic and
may become unstable on transmission to the next generation. In fragile X syndrome, CGG repeat lengths exceed 200,
resulting in silencing of FMR1 and absence of its protein product, fragile X mental retardation protein (FMRP). CGG repeat
lengths between 55 and 200 occur in fragile X premutation (FXPM) carriers and have a high risk of expansion to a full
mutation on maternal transmission. FXPM carriers have an increased risk for developing progressive neurodegenerative
syndromes and neuropsychological symptoms. FMR1 mRNA levels are elevated in FXPM, and it is thought that clinical
symptoms might be caused by a toxic gain of function due to elevated FMR1 mRNA. Paradoxically, FMRP levels decrease
moderately with increasing CGG repeat length in FXPM. Lowered FMRP levels may also contribute to the appearance of
clinical problems. We previously reported increases in regional rates of cerebral protein synthesis (rCPS) in the absence of
FMRP in an Fmr1 knockout mouse model and in a FXPM knockin (KI) mouse model with 120 to 140 CGG repeats in which
FMRP levels are profoundly reduced (80%–90%). To explore whether the concentration of FMRP contributes to the rCPS
changes, we measured rCPS in another FXPM KI model with a similar CGG repeat length and a 50% reduction in FMRP. In all
24 brain regions examined, rCPS were unaffected. These results suggest that even with 50% reductions in FMRP, normal
protein synthesis rates are maintained.
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Introduction
The (CGG)n-repeat sequence in the 50-untranslated
region of the fragile X mental retardation gene (FMR1)
on Xq27.3 is polymorphic. In the normal population, the
repeat sequence length is 5 to 54 and the gene product,
fragile X mental retardation protein (FMRP) has normal
expression (Fu et al., 1991). Individuals with fragile X
syndrome (FXS), the most common form of hereditary
intellectual disability and monogenic cause of autism,
have more than 200 CGG repeats resulting in gene
methylation, transcriptional silencing, and absence of
FMRP (Verkerk et al., 1991). This is known as the full
mutation. Individuals with (CGG)n between 55 and 200
are known as fragile X premutation (FXPM) carriers.
The gene remains unmethylated in these individuals and
transcription is not silenced, but there is a high risk of
expansion to a full mutation on maternal transmission.
Because the prevalence of FXPM in the general popula-
tion, approximately 1/290 males and 1/148 females
(Maenner et al., 2013), is much higher than that of
FXS, FXPM may have a greater impact on the general
population than FXS.
1Section on Neuroadaptation and Protein Metabolism, National Institute of
Mental Health, National Institutes of Health, Bethesda, MD, USA
2Department of Clinical Genetics, Erasmus MC, Rotterdam,
The Netherlands
Corresponding Author:
Carolyn B. Smith, Section on Neuroadaptation and Protein Metabolism,
National Institute of Mental Health, National Institutes of Health, 10 Center
Drive, Building 10, Room 2D54, Bethesda, MD 20892, USA.
Email: beebe@mail.nih.gov
ASN Neuro
July-September 2014: 1–8
! The Author(s) 2014
Reprints and permissions:
sagepub.co.uk/journalsPermissions.nav
DOI: 10.1177/1759091414551957
asn.sagepub.com
Creative Commons CC-BY: This article is distributed under the terms of the Creative Commons Attribution 3.0 License
(http://www.creativecommons.org/licenses/by/3.0/) which permits any use, reproduction and distribution of the work without further permission
provided the original work is attributed as specified on the SAGE and Open Access pages (http://www.uk.sagepub.com/aboutus/openaccess.htm).
XML Template (2014) [17.9.2014–3:03pm] [1–8]
//blrnas3.glyph.com/cenpro/ApplicationFiles/Journals/SAGE/3B2/ASNJ/Vol00000/140007/APPFile/SG-ASNJ140007.3d (ASN) [PREPRINTER stage]
FXPM carriers are at increased risk for developing
progressive neurodegenerative syndromes, including fra-
gile X-associated tremor/ataxia syndrome (FXTAS;
Hagerman et al., 2001) and fragile X-associated primary
ovarian insuﬃciency (FXPOI) in females (Allingham-
Hawkins et al., 1999). Further evidence suggests that
FXPM carriers have a higher incidence of neuropsycho-
logical symptoms (Cornish et al., 2005, 2009; Hunter
et al., 2008; Kogan et al., 2008). These features are
thought to be caused by a toxic gain of function of ele-
vated levels of CGG repeat-containing FMR1 mRNA
(Jin et al., 2003; Hessl et al., 2005; Brouwer et al.,
2008a; Hagerman, 2013). As FMRP levels moderately
decrease with increasing CGG repeat length (Tassone
et al., 2000; Peprah et al., 2010; Ludwig et al., 2014),
lowered FMRP levels could also contribute to clinical
symptoms (Ludwig et al., 2014).
To better understand FXPM, two expanded CGG
repeat knockin (KI) models have been generated in
mice (Bontekoe et al., 2001; Entezam et al., 2007). In
one (KIDutch), a region of the Fmr1 gene including the
endogenous repeat tract (CGG)8 was replaced with a
cloned human premutation allele (CGG)98 (Bontekoe
et al., 2001). The repeat tract in the other model
(KINIH) was generated by serial ligation of short, stable
CGGCCG repeats (Grabczyk and Usdin, 1999; Entezam
et al., 2007). As in the human disease, the KI mice in both
models exhibit repeat-length instabilities on transmission
to succeeding generations and a direct relationship
between repeat number and Fmr1 mRNA levels in
brain (Bontekoe et al., 2001; Entezam et al., 2007). KI
mice also display behavioral phenotypes similar to those
seen in human FXPM individuals, such as motor deﬁcits,
anxiety, and impairments of learning and memory (Van
Dam et al., 2005; Hunsaker et al., 2009, 2011, 2012; Qin
et al., 2011; Diep et al., 2012). FMRP levels tend to
decrease with increasing CGG repeat length, and in
both KI models, brain FMRP levels are decreased; the
eﬀect size varies across studies (Willemsen et al., 2003;
Brouwer et al., 2007, 2008a, 2008b; Entezam et al.,
2007; Qin et al., 2011; Berman et al., 2012; Ludwig
et al., 2014). Previously, we studied young adult, male
KINIH PM mice with CGG(120–140) and found that they
had a very similar behavioral phenotype to Fmr1 knock-
out (KO) mice (Qin et al., 2011). We found that young
adult KINIH mice exhibited hyperactivity in the open
ﬁeld, less general anxiety in both the open ﬁeld and ele-
vated zero maze, impaired learning and memory on a
passive avoidance test, and subtle deﬁcits on a test of
social interaction. Motor learning was normal as assessed
by the rotarod test. In our study, KINIH mice had two-
and sixfold increases in Fmr1 mRNA and drastic
decreases in levels of FMRP; FMRP levels in whole
brain were reduced to 15% of wild type (WT).
Additionally, regional rates of cerebral protein synthesis
(rCPS) measured in vivo were statistically signiﬁcantly
increased similar to our ﬁnding in Fmr1 KO mice
(Qin et al., 2005), suggesting that the decreased concen-
tration of FMRP may contribute to the KINIH pheno-
type. Our goal in the present study was to test how
the expanded CGG repeat sequence in Fmr1 aﬀects
rCPS in a model (KIDutch) in which FMRP levels are
reported to be either not aﬀected (Willemsen et al.,
2003) or moderately reduced (Brouwer et al., 2008a;
Berman et al., 2012).
Materials and Methods
Animals
The KIDutch mice generated by exchanging the murine
endogenous (CGG)8 with a human (CGG)98 (Bontekoe
et al., 2001) were obtained from Erasmus Medical
College. The genetic background was C57BL/6.
Animals for these experiments were bred in-house.
Brieﬂy, WT and KIDutch mice were produced by pairing
female mice heterozygous for the KIDutch allele with WT
males. This strategy yielded WT and KIDutch male mice in
the same litters. Mice were group housed in a central
facility and maintained under controlled conditions of
normal humidity and temperature with standard alternat-
ing 12-hr periods of light and darkness. All procedures
were carried out in accordance with the National
Institutes of Health Guidelines on the Care and Use of
Animals and an animal study protocol approved by the
National Institute of Mental Health Animal Care and
Use Committee.
Determination of CGG Repeat Size
DNA was extracted from mouse tail with Gentra
Puregene Mouse Tail Kit (Puregene, Gentra Systems,
Inc., Minneapolis, MN, USA) and kept in Tris-EDTA
(TE) buﬀer. The size of the CGG repeat tract was moni-
tored by polymerase chain reaction (PCR) with the pri-
mers CGG-F (50-CGGAGGCGCCGCTGCCAGG-30)
and CGG-R (50-TGCGGGCGCGCTCGAGGCCCAG-
30) as described previously (Hukema and Oostra, 2013).
Western Blotting
WT and KIDutch mice were anesthetized with sodium
pentobarbital (100mg/kg, i.p.) and decapitated. The cere-
bellum and cerebrum were separated and frozen in dry
ice. Frozen sections, 100 mm in thickness, were prepared
at 22C (Leica 1850 cryostat; Leica Microsystems,
Deerﬁeld, IL), and 11 regions were punched by means
of Harris Uni-Core (1.25mm; Electron Microscopy
Sciences, Hatﬁeld, PA). Regions were weighed and
homogenized in 1% (w/v) ice-cold tissue protein
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extraction reagent (T-PER) (Thermo Scientiﬁc,
Rockford, IL) with 1% Halt protease inhibitor cocktail
(Thermo Scientiﬁc) and 1% phosphatase inhibitor cock-
tail (Sigma-Aldrich, St. Louis, MO, USA). Homogenates
were centrifuged (12,000 g, 4C, 15min). The super-
natant fractions were collected as protein samples,
which were separated by NuPAGE on Bis–Tris gels and
subjected to Western blotting with a WesternBreeze
Chemiluminescent kit (Invitrogen, Carlsbad, CA).
FMRP was detected with a rabbit polyclonal antibody
to FMRP, ab17722 (Abcam Inc, Cambridge, MA).
Protein extracts from the brains of Fmr1 KO animals
were used as negative controls. Blots were quantiﬁed by
densitometry with MCID Analysis system (Interfocus
Imaging Ltd, Linton, Cambridge, UK).
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH
rabbit monoclonal antibody; Cell Signaling Technology,
Danvers, MA) was used as a loading control.
Regional Rates of Cerebral Protein Synthesis (rCPS)
We used the autoradiographic L-[1-14C] leucine method
to determine rCPS in young adult WT (n¼ 7) and KIDutch
(n¼ 7) mice as described previously (Qin et al., 2005).
Brieﬂy, mice under light isoﬂurane anesthesia were pre-
pared for studies by insertion of polyethylene catheters
into a femoral artery and vein. Mice recovered from the
surgery overnight and were permitted to move freely. The
experimental period was initiated by an intravenous pulse
injection of 100 mCi/kg of L-[1-14C]leucine (speciﬁc activ-
ity, 60mCi/mmol; Moravek Biochemicals, Brea, CA).
Timed arterial samples were collected during the follow-
ing 60min for determination of the time courses of
plasma concentrations of leucine and [14C]leucine. At
the end of the experimental interval, brains were
removed, frozen, and serial sections, 20 mm in thickness,
were prepared for quantitative autoradiography.
Autoradiograms were digitized (MCID Analysis,
Interfocus Imaging Ltd, Linton, Cambridge, UK), the
concentration of 14C in each region of interest was deter-
mined, and rCPS was calculated by means of the oper-
ational equation of the method (Smith et al., 1988). The
value of lambda in the equation was 0.603 (Qin et al.,
2005). Brain regions were identiﬁed by reference to a
mouse brain atlas (Paxinos and Franklin, 2001).
Statistical Analysis
Data are expressed as meanSEM. Statistically signiﬁ-
cant interactions were analyzed by repeated measures
(RM) analysis of variance (ANOVA). Data from
Western blots were analyzed for diﬀerences between WT
and KIDutch by means of one-tailed Student’s t tests. The
criterion for statistical signiﬁcance was p .05. We used
SPSS (IBM, Armonk, NY) for statistical analyses.
Results
FMRP Levels in Brain are Negatively Correlated
With Number of CGG Repeats
We determined the number of CGG repeats and whole
brain levels of FMRP in 10 KIDutch mice. The number of
CGG repeats ranged from 114 to 279, and FMRP levels
decreased from 59% to 14% of the mean of three WT
values (Figure 1(a) and (b)). We found a statistically
Figure 1. Effects of CGG repeat insertion on FMRP in brain
regions. (a) Change in FMRP/GAPDH in whole brain as % of WT
controls. KIDutch mice had CGG repeat lengths ranging from 119 to
279. The negative correlation (Pearson correlation coefficient,
.8571) is statistically significant (p< .002). The WT control FMRP/
GAPDH is the mean of two determinations (0.464, 0.481). (b)
Western blot of whole brain extracts from WT and KIDutch mice
with CGG repeats range 119 to 279. (c) Change in FMRP/GAPDH
ratios in whole brain and 12 subregions as % of WT controls.
KIDutch mice had CGG repeats range 119 to 151. Bars are the
mean SEM determined in three mice of each genotype. We used a
rabbit polycolonal antibody to FMRP (ab17722). FMRP¼ fragile X
mental retardation protein; WT¼wild type; GAPDH¼
glyceraldehyde-3-phosphate dehydrogenase; CX¼ cortex.
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signiﬁcant negative correlation between FMRP levels and
the number of CGG repeats (p< .002). For our studies of
rCPS, we used mice with CGG repeat lengths between
120 and 159 (Table 1). In mice with a similar range of
CGG repeat lengths (119–151), we found that average
brain FMRP levels were reduced to 49% of WT controls.
We also determined FMRP levels in 12 brain regions
from three KIDutch mice (CGG repeat lengths between
108 and 128) and found that levels ranged from 44% to
77% of WT controls (Figure 1(b)). Frontal association
cortex and thalamus had the greatest decreases (47%,
44% of WT), and hypothalamus had the mildest decrease
(77% of WT).
Unaltered rCPS in KIDutch Mice
At the time of rCPS determination, physiological vari-
ables in WT and KIDutch mice were well matched with
respect to age, body weight, and other physiological vari-
ables measured (Table 1).
To compare the eﬀects of the expanded CGG repeat in
KIDutch mice to its eﬀects in KINIH mice, we analyzed
rCPS in the same 19 regions studied in our previous
study with the addition of motor cortex and stratum
radiatum of the dorsal and ventral hippocampus. In the
present study, we determined rCPS in 21 brain regions
including the dorsal hippocampus as a whole, the ventral
hippocampus as a whole, four subregions of the dorsal
and ventral hippocampus, six cortical areas, and ﬁve
other regions (Figures 2 and 3). Results of rCPS deter-
minations were analyzed by means of RM ANOVA with
brain region as the within-subjects factor and genotype as
the between-subjects factor. The interaction between
region and genotype was not statistically signiﬁcant,
F(2.7, 18.9)¼ 1.154, p¼ .35, and there was no main
eﬀect of genotype, F(1, 7)¼ 0.676, p¼ .44. As expected
from previous studies in which we measured rCPS in vivo,
we did ﬁnd a statistically signiﬁcant eﬀect of region,
F(2.7, 18.9)¼ 204.86, p< .001, indicating that rCPS
varies across brain regions. It is evident from the bar
graphs (Figure 2) and the autoradiographs (Figure 3)
that the mean values of rCPS in the two groups (WT
and KIDutch) are very similar.
Discussion
The results of the present study show that in a mouse
model of FXPM in which the CGG repeat length was
between 120 and 159, in vivo rCPS measured in awake,
behaving mice at 4 to 5 months of age were not diﬀerent
from those of WT control mice. Rates were normal des-
pite a 50% decrease in brain FMRP levels. Our study
suggests that there may be a threshold level of FMRP
necessary for the maintenance of normal rates of protein
synthesis.
We used the in vivo quantitative autoradiographic leu-
cine method (Smith et al., 1988) to quantify rates of pro-
tein synthesis in our studies. With this methodology, we
can measure steady-state rates of ongoing protein synthe-
sis in conscious functioning mice. Measurements are
average rates of leucine incorporation into all tissue pro-
teins; our measurements do not target speciﬁc proteins.
The relative contribution of an individual protein to the
overall rCPS is weighted by both its fractional contribu-
tion to total tissue protein and its half-life in the tissue.
The fact that we did not ﬁnd increased rCPS in the
KIDutch mice does not exclude the possibility that the
synthesis of speciﬁc proteins may be aﬀected, either
increased or decreased. One of the advantages of the
autoradiographic method is that it enables us to measure
rCPS in all regions of the brain. The spatial resolution of
the autoradiographic method is 50 mm (Smith, 1983). This
permits us to distinguish speciﬁc nuclei and cell layers,
including dendritic-rich and cell body layers. We cannot,
however, distinguish speciﬁc cell types within a layer.
The absence of FMRP is at the biochemical core of
FXS. FMRP is a polyribosome-associated RNA-binding
protein, suggesting that it may play a role in regulating
translation. In in vitro model systems (Laggerbauer et al.,
2001; Li et al., 2001), FMRP binds its target mRNAs and
negatively regulates their translation. FMRP has been
shown to reversibly stall ribosomes speciﬁcally on its
target mRNAs during elongation (Darnell et al., 2011).
FMRP also recruits cytoplasmic FMRP-interacting pro-
tein (CYFIP1) to block formation of the eIF4F complex
preventing translation initiation (Napoli et al., 2008).
FMRP also can recruit RNA-induced silencing complex
(RISC) to inhibit translation (Caudy et al., 2002).
Consistent with this role for FMRP as a suppressor of
translation, elevated rates of protein synthesis measured
in the intact nervous system have been demonstrated in
Fmr1 KO mice (Qin et al., 2005). The most aﬀected
regions were hippocampus, hypothalamus, thalamus,
Table 1. Physiological Variables.
Wild type (7) Knockin (7)
Age (days) 130 0.5 129 0.9
Body weight (g) 31.0 1.8 32.8 0.7
Arterial plasma glucose
concentration (mM)
5.3 0.4 5.8 0.3
Arterial blood hematocrit (%) 45 1 44 1
Mean arterial blood
pressure (mm Hg)
111 1 113 1
CGG repeat length ND 137 6
Note. Physiological variables were measured at the time of rCPS study.
Values are mean SEM for the number of mice indicated in parentheses.
ND¼ not determined.
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Figure 2. Regional rates of cerebral protein synthesis in WT (open bars) and KIDutch (filled bars) mice. Bars represent the means SEM
for seven mice in each group except for the paraventricular nucleus of the hypothalamus with five WT mice and four KI mice. Data were
analyzed by means of RM ANOVA with region as the within-subjects factor and genotype as the between-subjects factor. The interaction
between region and genotype, F(2.7, 18.9)¼ 1.154, p¼ .35, was not statistically significant, and we found no statistically significant main
effect of genotype, F(1, 7)¼ 0.676, p¼ .44. The main effect of region, F(2.7, 18.9)¼ 204.86, p< .001, was statistically significant.
dHi¼ dorsal hippocampus; dCA1¼ dorsal CA1 pyramidal cell layer; dCA2&3¼ dorsal CA2&3 pyramidal cell layer; dRad¼ dorsal stratum
radiatum; dDG¼ dorsal dentate gyrus; vHi¼ ventral hippocampus; vCA1¼ ventral CA1 pyramidal cell layer; vCA2&3¼ ventral CA2&3
pyramidal cell layer; vRad¼ ventral stratum radiatum; vDG¼ ventral dentate gyrus; FrCx¼ frontal association cortex; MCx¼ primary
motor cortex; PFrCx¼medial prefrontal cortex; SmCx¼ somatosensory cortex; PPCx¼ posterior parietal cortex; CbCx¼ cerebellar
cortex; Str¼ striatum; BSt¼ bed nucleus of the stria terminalis; BLA¼ basolateral amygdala; Th¼ thalamus; PVN¼ paraventricular nucleus
of the hypothalamus.
Figure 3. Digitized autoradiographic images color coded for rCPS at the level of dorsal hippocampus: (a and c) WT-C and (b and d)
KIDutch. Color bar applies to all four images. Scale bar in (b) (0.5mm) applies to (a) and (b), and scale bar in (d) (1mm) applies to (c) and (d).
Images in (a) and (b) are enlarged subsections through the hippocampus taken from images in (c) and (d), respectively. Lines in (b) delineate
the CA1 and the CA2-3 sectors of the pyramidal cell layer of the hippocampus. rCPS¼ regional rates of cerebral protein synthesis.
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amygdala, and frontal and parietal cortex. Studies in hip-
pocampal slices from Fmr1 KO mice conﬁrm increased
incorporation rates (Do¨len et al., 2007). This core patho-
physiological change in the disease might be used as a
biomarker of eﬀective drug treatment (Liu et al., 2012;
Michalon et al., 2012).
We were interested in knowing whether changes in
rCPS occur in FXPM because of reports that patients
with FXPM have symptoms suggesting a milder form
of FXS (Cornish et al., 2005; Hunter et al., 2008;
Kogan et al., 2008; Cornish et al., 2009) and because
FMRP concentrations in lymphocytes may be decreased
in these patients (Tassone et al., 2000). We hypothesized
that with reduced concentrations of FMRP, rCPS might
be increased but to a lesser extent than seen in Fmr1 KO
mice. In our previous study of the KINIH mouse model of
FXPM with CGG repeat lengths between 120 and 140,
we found that FMRP levels in brain were reduced by
80% to 90% of WT and rCPS were increased (106–
120% of WT) similar to changes we had seen in Fmr1
KO mice. KINIH animals also had a behavioral pheno-
type comparable to Fmr1 KO mice. In the KIDutch mouse
model, we selected mice with CGG repeat lengths
between 120 and159 because animals with repeat lengths
in this range had FMRP levels about 50% of WT. The
eﬀect that we found on FMRP levels was similar to pre-
vious reports in this model. In KIDutch mice with
CGG(100–150), a 40% decrease in brain FMRP (p¼ .11)
was reported in 1-year-old animals (Brouwer et al.,
2008a). In KIDutch mice with CGG(84–210), Fmr1 mRNA
expression was increased in brain by approximately
1.4 fold compared with WT mice (p< .05), whereas
brain levels of FMRP were reduced by 28% (Berman
et al., 2012).
Controlling for CGG repeat length, background
strain, and age of the animals, the two FXPM mouse
models, KIDutch and KINIH, yield similar results with
respect to changes in Fmr1 mRNA levels and changes
in dendritic structure, but with respect to rCPS and
behavioral phenotype, the two models diverge. In the
KIDutch model, Fmr1 mRNA levels in brain were
increased threefold over WT (Willemsen et al., 2003).
Increases were similar in the KINIH model, two- to four-
fold in most brain regions (Qin et al., 2011). Compared
with WT mice, KIDutch mice showed fewer dendritic
branches proximal to the soma, reduced total dendritic
length, and a higher frequency of longer dendritic spines
(Berman et al., 2012). KINIH mice showed reduced den-
dritic complexity and increased dendritic spine length in
pyramidal neurons in medial frontal cortex, hippocam-
pus, and basal amygdala (Qin et al., 2011). In the present
study, we did not determine the behavioral phenotype of
KIDutch animals. Others have shown that KIDutch mice
(CGG repeat length 106–123) are not impaired on the
Morris water maze, passive avoidance test, open ﬁeld
test, and tests of neuromotor performance at 140 days
of age (Van Dam et al., 2005), although there are some
deﬁcits on the Morris water maze and open ﬁeld tests that
occur as the animals age. Further, tests of KIDutch mice
with CGG repeat lengths between 80 and 180 (Hunsaker
et al., 2009) indicate some subtle deﬁcits in spatial infor-
mation processing at 84 and 168 days of age that become
more extensive in older animals. Young adult KINIH mice
had a very similar behavioral phenotype to Fmr1 KO
mice (Qin et al., 2011), with hyperactivity, reduced anx-
iety, impaired social interactions, and deﬁcits on passive
avoidance test of learning and memory.
The reason for decreased levels of FMRP in the pres-
ence of excess Fmr1 mRNA is not understood, but it is
thought that transcripts with expanded repeats may
impede the linear 40 S migration along the 50-untrans-
lated region (Feng et al., 1995). The similarities in the
expanded repeat sequences and Fmr1 mRNA levels in
the two models, however, cannot explain the diﬀerence
in FMRP levels. Moreover, in the generation of both
models, the neo cassette was removed by crossing KI
mice with mice expressing Cre recombinase, so the
changes to Fmr1 were minimal in both models. It has
recently been reported that the KINIH model, but not
the KIDutch model, retains a stop codon 18 bp before
the CGG repeat (Todd et al., 2013). Consistent with
this diﬀerence, FMRpolyG is produced in KIDutch mice
likely through a repeat-associated non-AUG-initiated
(RAN) translation mechanism. How the synthesis of
FMRpolyG might positively inﬂuence FMRP levels is
not clear. One proposal is that translation through the
repeat may facilitate Fmr1 translation by assisting RNA
unwinding by means of helicase recruitment (Todd et al.,
2013). With CGG repeat lengths in the normal range, the
polyglycine peptides produced in this process may be
readily cleared from cells, but expanded repeats (50–200
CGG) produce larger polyglycine proteins that with time
accumulate in the cell and are cytotoxic. The decreased
levels of FMRP and the absence of FMRpolyG in the
KINIH may suggest that the RAN translation mechanism
is important for translation of Fmr1 in the presence of an
expanded CGG repeat sequence.
The present and previous studies of the KIDutch model
(Brouwer et al., 2008a; Berman et al., 2012) are in accord
with each other with respect to FMRP levels in brains.
Our current study suggests that FMRP at 50% of WT
levels is suﬃcient for normal cerebral protein synthesis
rates and what appears to be normal brain function in
young adult mice.
Conclusions
Our study of the adult male KIDutch mouse model of
FXPM with 120 and 159 CGG repeats showed that
in vivo rCPS were normal despite a 50% decrease in
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brain FMRP levels. These results suggest that there may
be a threshold level of FMRP necessary for the mainten-
ance of normal rates of protein synthesis in the nervous
system. As animal’s age and FMRP levels in brain
decline, further symptoms may unfold.
Summary
In a fragile X premutation mouse model, regional rates of
cerebral protein synthesis rates (rCPS) were normal des-
pite 50% fragile X mental retardation protein (FMRP)
reductions. Results suggest a threshold level of FMRP
may be necessary for maintenance of rCPS. With aging
and reduced FMRP, symptoms may unfold.
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